“With four Phase III studies underway and obstructive sleep apnea set to initiate this year, we are well positioned to deliver a robust and comprehensive clinical knowledge base.”

In context

“p dose escalation approach to optimize tolerability. Enrollment momentum for chronic weight management is strong across multiple geographies, reflecting broad investigator enthusiasm, participant interest in these trials and significant remaining unmet need. Since June, we initiated two additional Phase III studies. The first, MARITIME-CV evaluates cardiovascular outcomes in adults living with atherosclerotic cardiovascular disease and obesity or overweight. The second, MARITIME-HF, evaluates reduction of heart failure events and cardiovascular risk in adults living with heart failure with a preserved or mildly reduced ejection fraction and obesity. In summary, MariTide represents a promising treatment advance for people living with obesity, obesity-related conditions and type 2 diabetes. With four Phase III studies underway and obstructive sleep apnea set to initiate this year, we are well positioned to deliver a robust and comprehensive clinical knowledge base. Beyond MariTide, in general medicine, we remain excited about data from the Repatha VESALIUS Phase III primary prevention study expected later this year. Turning to olpasiran, our promising best-in-class small interfering RNA medicine targeting Lp(a), the fully enrolled event-driven OCEAN(a) Phase III cardiovascular outcome study continues to mature. This medicine and study reflect our precision medicine approach to cardiovascular risk reduction in patients with elevated Lp(a) levels. Moving on to our rare disease portfolio on UPLIZNA, we look forward to the upcoming December 14 PDUFA date for generalized myasthenia gravis, recognizing ever more the significant unmet need for durable, convenient therapies consistently highlighted to us by treating physicians. We are pleased by the Europea”